COMPASS Pathways plc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how the company is spending money and progressing toward drug approval.
Detailed financial report lets investors track the company's cash, assets, and shareholder ownership.
Test results for depression drug show progress toward FDA approval, which could make the company valuable.
Shareholders vote on company leadership and major decisions at the annual meeting.
Quarterly earnings show company progress and cash spending in early 2026.
Detailed financial report lets investors track the company's cash, assets, and shareholder ownership.
Annual report shows total company performance, cash status, and strategic plans for investors.
Stocky reads COMPASS Pathways plc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
COMPASS Pathways plc's most recent tracked filing was a 8-K on 5 Aug 2026: Reports Q2 2026 financial results for six months ended June 30.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.